Explore 3 Stock Ideas & Industry Insights Download Free Report

Announcements

Viemed Files Q3 2026 Results Report and Investor Deck

Viemed Healthcare, Inc. filed a Current Report on Form 8-K with the SEC on November 4, 2026, disclosing its financial results for the three and nine months ended September 30, 2026, along with a Financial Supplement and an Investor Deck Presentation.

Aakashdeep | 04 November 2026

Tutor Perini Q3 2026: Revenue Rises to $1.72 Billion

Tutor Perini Corporation filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 4, 2026, reporting third-quarter revenue of $1,720,256 thousand and net income attributable to the company of $20,701 thousand.

Shwetambri Chauhan | 04 November 2026

Tutor Perini Files Q3 2026 Earnings Report 8-K

Tutor Perini Corporation filed a Form 8-K with the SEC on November 4, 2026, disclosing the issuance of a press release announcing its financial results for the quarter ended September 30, 2026.

Manish Choudhary | 04 November 2026

AppLovin Stockholders Approve Nevada Reincorporation

AppLovin Corporation filed a Form 8-K on November 4, 2026, disclosing that certain stockholders approved a reincorporation from Delaware to Nevada by written consent on October 29, 2026, and separately announced financial results for the quarter ended September 30, 2026.

Aditi Sarkar | 04 November 2026

Summit Therapeutics Files Legality Opinion for Stock Offering

Summit Therapeutics Inc. filed a current report on November 4, 2026, to submit the legal opinion of Baker & Hostetler LLP relating to the legality of a common stock issuance connected to a prospectus supplement filed under the company's automatic shelf registration statement.

Shwetambri Chauhan | 04 November 2026

Summit Therapeutics Doubles Authorized Shares to 2 Billion

Summit Therapeutics Inc. filed a Form 8-K on November 4, 2026, disclosing a stockholder-approved amendment to its Restated Certificate of Incorporation that doubles authorized common stock from 1,000,000,000 to 2,000,000,000 shares, alongside the release of its third-quarter 2026 financial results.

Anjali Anand | 04 November 2026

Summit Therapeutics Q3 2026: Balance Sheet Snapshot

Summit Therapeutics Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on November 4, 2026, disclosing condensed consolidated financial statements and related information.

Aditi Sarkar | 04 November 2026

Ascent Industries Q3 2026: Net Sales Rise to $27.1M

Ascent Industries Co. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 4, 2026, reporting a return to operating income from continuing operations in the third quarter.

Nitish Kishor | 04 November 2026

Geron Q3 2026: First Quarterly Profit Since RYTELO Launch

Geron Corporation filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 4, 2026, reporting its first quarterly net income since the commercial launch of RYTELO.

Nitish Kishor | 04 November 2026

Vir Biotechnology Q3 2026: Total Assets Rise to $1.11 Billion

Vir Biotechnology, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 4, 2026, reporting condensed consolidated financial statements for the third quarter and nine months ended September 30, 2026.

Manish Choudhary | 04 November 2026
Support

Hi! How can we help you today?

Loading…